Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autoimmune Nervous System Disorder Clear all
Completed Not applicable Interventional

Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis

NCT03306875
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cognitive Training
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Sep 28, 2026, 5:07 PM EDT
Completed No phase listed Observational

Maintenance Plasma Exchange for Neuromyelitis Optica

NCT01500681
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
Interventions
Plasma exchange (PLEX)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2021 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

NCT03737812
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
elezanumab, placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Berkeley, California • Carlsbad, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 28, 2026, 5:07 PM EDT
Terminated No phase listed Observational

Gut Microbiome and Depression

NCT05808101
View directory record Official record
Conditions
Multiple Sclerosis, Depression
Interventions
Neuro-QoL T-score determination
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 28, 2026, 5:07 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

NCT04378075
View directory record Official record
Conditions
Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions
Vatiquinone, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Up to 20 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 1Phase 2 Interventional

Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain

NCT02012439
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mindfulness Based Cognitive Therapy, Cognitive Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 28, 2026, 5:07 PM EDT
Recruiting Phase 4 Interventional

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

NCT07609719
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
OCR SC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Cordova, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Active, not recruiting No phase listed Observational

Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis

NCT06930339
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Portable Neuromodulation Stimulator (PoNS)
Device
Lead sponsor
Helius Medical Inc
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Newtown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 28, 2026, 5:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

NCT02017808
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Early Phase 1 Interventional

Metformin Treatment in Progressive Multiple Sclerosis

NCT05349474
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 28, 2026, 5:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis Patients

NCT00094068
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 5:07 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

NCT07465289
View directory record Official record
Conditions
Ocular Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Study of SPARC1103 in Subjects With Spasticity

NCT02027025
View directory record Official record
Conditions
Spasticity
Interventions
SPARC1103 low dose, SPARC1103 high dose, SPARC Placebo
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
15
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Emotion Regulation Skills Training for Individuals With MS and Their Support Partners

NCT03934489
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
PERSIST, Facilitated Peer Support
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners

NCT05951985
View directory record Official record
Conditions
Neurologic Disorder, Parkinson Disease, Spinal Cord Injuries, Spina Bifida, Stroke, Poliomyelitis, Multiple Sclerosis, Brain Injuries
Interventions
HIFT
Behavioral
Lead sponsor
Arkansas Colleges of Health Education
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Smith, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 28, 2026, 5:07 PM EDT
Enrolling by invitation Not applicable Interventional

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis

NCT06441617
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
Online Program for Fatigue
Device
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Other
Eligibility
22 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Waltham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT02222948
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Vatelizumab, Placebo (for Vatelizumab)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional Results available

A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis

NCT01918800
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fatigue: Take control, MS: Take Control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Gainesville, Florida • Baltimore, Maryland • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Not applicable Interventional

Modafinil in Multiple Sclerosis

NCT00142402
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Modafinil
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 28, 2026, 5:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Childhood-Onset Obsessive-Compulsive Disorder

NCT00044239
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 12 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
4
States / cities
Little Rock, Arkansas • Gainesville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

NCT02269930
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
peginterferon beta-1a, Rebif
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 1, 2015 · Synced Sep 28, 2026, 5:07 PM EDT
Recruiting Early Phase 1 Interventional

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

NCT06629428
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab
Drug
Lead sponsor
Georgia State University
Other
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 28, 2026, 5:07 PM EDT
Completed Phase 2 Interventional Results available

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03355365
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Intrathecal MSC-NP injection, Intrathecal saline injection
Biological · Other
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 28, 2026, 5:07 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biobank For MS And Other Demyelinating Diseases

NCT00445367
View directory record Official record
Conditions
Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Interventions
Not listed
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Other
Eligibility
Not listed
Enrollment
3,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2036
U.S. locations
10
States / cities
Phoenix, Arizona • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 28, 2026, 5:07 PM EDT